{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:09:29Z","timestamp":1787749769301,"version":"build-2784847793"},"reference-count":183,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2008, a dedicated American Thoracic Society\/European Respiratory Society task force published a paper on the possible use and limitations of clinical outcomes and biomarkers to evaluate the impact of pharmacological therapy in patients with chronic obstructive pulmonary disease. Since then, our scientific understanding of chronic obstructive pulmonary disease has increased considerably; there has been a progressive shift from a one-size-fits-all diagnostic and therapeutic approach to a personalized approach; and many new treatments currently in development will require new endpoints to evaluate their efficacy adequately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The emergence of several new relevant outcome measures motivated the authors to review advances in the field and highlight the need to update the content of the original report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors separately created search strategies for the literature, primarily based on their opinions and assessments supported by carefully chosen references. No centralized examination of the literature or uniform criteria for including or excluding evidence were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Endpoints, outcomes, and biomarkers have been revisited. The limitations of some of those reported in the American Thoracic Society\/European Respiratory Society task force document have been highlighted. In addition, new tools that may be useful, especially in evaluating personalized therapy, have been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Because the \u201clabel-free\u201d treatable traits approach is becoming an important step toward precision medicine, future clinical trials should focus on highly prevalent treatable traits, and this will influence the choice of outcomes and markers to be considered. The use of the new tools, particularly combination endpoints, could help better identify the right patients to be treated with the new drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202303-0400so","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T20:02:00Z","timestamp":1685131320000},"page":"374-394","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":37,"title":["An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society\/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials"],"prefix":"10.1093","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Barnes","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Pulmonology and Cystic Fibrosis Unit, Internal Medicine Department, Foundation Scientific Institute for Research, Hospitalization and Healthcare Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-8371","authenticated-orcid":false,"given":"Bartolome","family":"Celli","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[{"name":"Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Miller","sequence":"additional","affiliation":[{"name":"COPD Foundation, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-9520","authenticated-orcid":false,"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitari Vall d\u2019Hebron\/Vall d\u2019Hebron Institut de Recerca, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[{"name":"Sackler Institute of Pulmonary Pharmacology, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-8062","authenticated-orcid":false,"given":"Ruth","family":"Tal-Singer","sequence":"additional","affiliation":[{"name":"TalSi Translational Medicine Consulting, LLC, Media, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"2026012204421862300_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib2","first-page":"1","article-title":"Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care","volume":"59","author":"National Collaborating Centre for Chronic Conditions","year":"2004","journal-title":"Thorax"},{"key":"2026012204421862300_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib4","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2022"},{"key":"2026012204421862300_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/thoraxjnl-2014-205507","article-title":"The path to personalised medicine in COPD","volume":"69","author":"Agusti","year":"2014","journal-title":"Thorax"},{"key":"2026012204421862300_bib6","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.07-3059","article-title":"The many \u201csmall COPDs\u201d: COPD should be an orphan disease","volume":"134","author":"Rennard","year":"2008","journal-title":"Chest"},{"key":"2026012204421862300_bib8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0140-6736(09)61541-5","article-title":"Time to define the disorders of the syndrome of COPD","volume":"374","author":"Beasley","year":"2009","journal-title":"Lancet"},{"key":"2026012204421862300_bib9","doi-asserted-by":"crossref","first-page":"00117-2017","DOI":"10.1183\/23120541.00117-2017","article-title":"Natural history of COPD: gaps and opportunities","volume":"3","author":"Agust\u00ed","year":"2017","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/thoraxjnl-2013-203602","article-title":"Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?","volume":"69","author":"Vanfleteren","year":"2014","journal-title":"Thorax"},{"key":"2026012204421862300_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S2213-2600(15)00254-4","article-title":"The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?","volume":"3","author":"Bateman","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/COPD.S91742","article-title":"Prevalence of chronic obstructive pulmonary disease in asymptomatic smokers","volume":"10","author":"Sansores","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib13","first-page":"1494","article-title":"Asymptomatic patients of chronic obstructive pulmonary disease in China","volume":"123","author":"Lu","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"2026012204421862300_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp1114866","article-title":"Preparing for precision medicine","volume":"366","author":"Mirnezami","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012204421862300_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40291-014-0100-9","article-title":"Defining phenotypes in COPD: an aid to personalized healthcare","volume":"18","author":"Segreti","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"2026012204421862300_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40291-017-0266-z","article-title":"The challenges of precision medicine in COPD","volume":"21","author":"Cazzola","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"2026012204421862300_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCP.0000000000000238","article-title":"Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype","volume":"22","author":"Russell","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2026012204421862300_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2020.1804364","article-title":"Endo-phenotyping of COPD patients","volume":"15","author":"Barnes","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2026012204421862300_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1164\/rccm.201606-1179PP","article-title":"Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease","volume":"194","author":"Singh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib20","author":"European Medicines Agency","year":"2012"},{"key":"2026012204421862300_bib21","doi-asserted-by":"crossref","first-page":"1900108","DOI":"10.1183\/13993003.00108-2019","article-title":"Defining severe obstructive lung disease in the biologic era: an endotype-based approach","volume":"54","author":"Martin","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","article-title":"Towards the elimination of chronic obstructive pulmonary disease: a Lancet commission","volume":"400","author":"Stolz","year":"2022","journal-title":"Lancet"},{"key":"2026012204421862300_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(22)01660-9","article-title":"Classification of COPD: fostering prevention and precision medicine in the Lancet Commission on COPD","volume":"400","author":"Brusselle","year":"2022","journal-title":"Lancet"},{"key":"2026012204421862300_bib24","author":"U.S. Food and Drug Administration (FDA)","year":"2022"},{"key":"2026012204421862300_bib25","author":"European Medicines Agency","year":"2021"},{"key":"2026012204421862300_bib26","author":"Pharmaceuticals and Medical Devices Agency","year":"2021"},{"key":"2026012204421862300_bib27","author":"COPD Foundation","year":"2022"},{"key":"2026012204421862300_bib28","doi-asserted-by":"crossref","first-page":"1802058","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib30","doi-asserted-by":"crossref","first-page":"106572","DOI":"10.1016\/j.rmed.2021.106572","article-title":"Moving towards a Treatable Traits model of care for the management of obstructive airways diseases","volume":"187","author":"Agusti","year":"2021","journal-title":"Respir Med"},{"key":"2026012204421862300_bib31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","article-title":"Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management","volume":"385","author":"Woodruff","year":"2015","journal-title":"Lancet"},{"key":"2026012204421862300_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41533-021-00236-w","article-title":"Pulmonary function testing in COPD: looking beyond the curtain of FEV1","volume":"31","author":"Kakavas","year":"2021","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026012204421862300_bib33","doi-asserted-by":"crossref","first-page":"00243-2018","DOI":"10.1183\/23120541.00243-2018","article-title":"Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study","volume":"5","author":"Kostikas","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib34","doi-asserted-by":"crossref","first-page":"00438-2020","DOI":"10.1183\/23120541.00438-2020","article-title":"Treatable traits qualifying for nonpharmacological interventions in COPD patients upon first referral to a pulmonologist: the COPD sTRAITosphere","volume":"6","author":"van \u2018t Hul","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","article-title":"Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease","volume":"49","author":"Donohue","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012204421862300_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/COPD.S284720","article-title":"Longitudinal FEV1 and exacerbation risk in COPD: quantifying the association using joint modelling","volume":"16","author":"Zhudenkov","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2213-2600(18)30529-0","article-title":"Lung function trajectories in health and disease","volume":"7","author":"Agusti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.202107-1663SO","article-title":"Treatment trials in young patients with chronic obstructive pulmonary disease and pre- chronic obstructive pulmonary disease patients: time to move forward","volume":"205","author":"Martinez","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S2213-2600(18)30196-6","article-title":"Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study","volume":"6","author":"Koo","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib41","doi-asserted-by":"crossref","first-page":"1900753","DOI":"10.1183\/13993003.00753-2019","article-title":"Technical standards for respiratory oscillometry","volume":"55","author":"King","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib42","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/s41598-021-84028-9","article-title":"Comparative evaluation of expiratory airflow limitation between patients with COPD and BE using IOS","volume":"11","author":"Dos Santos","year":"2021","journal-title":"Sci Rep"},{"key":"2026012204421862300_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.rmed.2018.05.004","article-title":"What can we learn about COPD from impulse oscillometry?","volume":"139","author":"Lipworth","year":"2018","journal-title":"Respir Med"},{"key":"2026012204421862300_bib44","doi-asserted-by":"crossref","first-page":"e8543","DOI":"10.1097\/MD.0000000000008543","article-title":"Impulse oscillometry system as an alternative diagnostic method for chronic obstructive pulmonary disease","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026012204421862300_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/COPD.S280157","article-title":"Small airways disease, biomarkers and COPD: where are we?","volume":"16","author":"Chukowry","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12931-021-01662-7","article-title":"Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function","volume":"22","author":"Li","year":"2021","journal-title":"Respir Res"},{"key":"2026012204421862300_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.rmed.2011.01.010","article-title":"Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results","volume":"105","author":"Crim","year":"2011","journal-title":"Respir Med"},{"key":"2026012204421862300_bib48","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1378\/chest.124.5.1743","article-title":"Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes","volume":"124","author":"Celli","year":"2003","journal-title":"Chest"},{"key":"2026012204421862300_bib49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O\u2019Donnell","year":"2006","journal-title":"Chest"},{"key":"2026012204421862300_bib50","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib51","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1164\/rccm.200707-1064OC","article-title":"Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease","volume":"177","author":"Ofir","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","article-title":"Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial","volume":"6","author":"Hohlfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1164\/rccm.200407-867OC","article-title":"Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease","volume":"171","author":"Casanova","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.201803-0590OC","article-title":"A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE)","volume":"198","author":"Criner","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pupt.2012.10.010","article-title":"Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists","volume":"26","author":"Cazzola","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012204421862300_bib56","doi-asserted-by":"crossref","first-page":"14799731211056340","DOI":"10.1177\/14799731211056340","article-title":"Diffusing capacity in chronic obstructive pulmonary disease assessment: a meta-analysis","volume":"18","author":"Ni","year":"2021","journal-title":"Chron Respir Dis"},{"key":"2026012204421862300_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000512728","article-title":"Triple therapy is also effective in real-world when used in chronic obstructive pulmonary disease patients who are frequent exacerbators","volume":"100","author":"Cazzola","year":"2021","journal-title":"Respiration"},{"key":"2026012204421862300_bib58","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1378\/chest.125.5.1714","article-title":"Assessment of emphysema in COPD: a functional and radiologic study","volume":"125","author":"Cerveri","year":"2004","journal-title":"Chest"},{"key":"2026012204421862300_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12931-019-1237-1","article-title":"Relationship between diffusion capacity and small airway abnormality in COPDGene","volume":"20","author":"Criner","year":"2019","journal-title":"Respir Res"},{"key":"2026012204421862300_bib60","first-page":"477","article-title":"Effect of bronchodilatation on single breath pulmonary uptake of carbon monoxide in chronic obstructive pulmonary disease","volume":"1","author":"Baldi","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib61","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.rmed.2007.02.007","article-title":"Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists","volume":"101","author":"Santus","year":"2007","journal-title":"Respir Med"},{"key":"2026012204421862300_bib62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000512064","article-title":"Real-Life clinical and functional effects of fluticasone furoate\/umeclidinium\/vilanterol-combined triple therapy in patients with chronic obstructive pulmonary disease","volume":"100","author":"Pelaia","year":"2021","journal-title":"Respiration"},{"key":"2026012204421862300_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12931-022-01949-3","article-title":"Effect of indacaterol\/glycopyrronium on ventilation and perfusion in COPD: a randomized trial","volume":"23","author":"Singh","year":"2022","journal-title":"Respir Res"},{"key":"2026012204421862300_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.phrs.2018.05.010","article-title":"Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD","volume":"133","author":"Santus","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026012204421862300_bib65","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.chest.2021.03.069","article-title":"Natural course of the diffusing capacity of the lungs for carbon monoxide in COPD: importance of sex","volume":"160","author":"Casanova","year":"2021","journal-title":"Chest"},{"key":"2026012204421862300_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1465-9921-7-52","article-title":"Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"7","author":"Gan","year":"2006","journal-title":"Respir Res"},{"key":"2026012204421862300_bib67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17512433.2021.1888713","article-title":"Sex differences in COPD management","volume":"14","author":"Matera","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026012204421862300_bib68","doi-asserted-by":"crossref","first-page":"00272-2021","DOI":"10.1183\/23120541.00272-2021","article-title":"Oximetry neither to prescribe long-term oxygen therapy nor to screen for severe hypoxaemia","volume":"7","author":"Lacasse","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/jcm8030340","article-title":"\u201cCan do\u201d versus \u201cdo do\u201d: a novel concept to better understand physical functioning in patients with chronic obstructive pulmonary disease","volume":"8","author":"Koolen","year":"2019","journal-title":"J Clin Med"},{"key":"2026012204421862300_bib70","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1183\/13993003.00745-2015","article-title":"Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement","volume":"47","author":"Puente-Maestu","year":"2016","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib71","first-page":"126","article-title":"Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research","volume":"100","author":"Caspersen","year":"1985","journal-title":"Public Health Rep"},{"key":"2026012204421862300_bib72","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/COPD.S130195","article-title":"Accelerometer- versus questionnaire-based assessment of physical activity and their changes over time in patients with COPD","volume":"12","author":"Sievi","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib73","first-page":"321","article-title":"Systematic review of the association between laboratory- and field-based exercise tests and lung function in patients with chronic obstructive pulmonary disease","volume":"2","author":"Bell","year":"2015","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib74","doi-asserted-by":"crossref","first-page":"180101","DOI":"10.1183\/16000617.0101-2018","article-title":"ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases","volume":"28","author":"Radtke","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026012204421862300_bib75","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4187\/respcare.06336","article-title":"A high degree of dyspnea is associated with poor maximum exercise capacity in subjects with COPD with the same severity of air-flow obstruction","volume":"64","author":"Crisafulli","year":"2019","journal-title":"Respir Care"},{"key":"2026012204421862300_bib76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pulmoe.2021.06.001","article-title":"The COPD Assessment Test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients","volume":"29","author":"Pisi","year":"2023","journal-title":"Pulmonology"},{"key":"2026012204421862300_bib77","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1378\/chest.07-2050","article-title":"The 6-min walk distance, peak oxygen uptake, and mortality in COPD","volume":"132","author":"Cote","year":"2007","journal-title":"Chest"},{"key":"2026012204421862300_bib78","first-page":"155","article-title":"Physical activity monitoring in patients with chronic obstructive pulmonary disease","volume":"1","author":"Liao","year":"2014","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib79","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/jcm9113497","article-title":"Data reproducibility and effectiveness of bronchodilators for improving physical activity in COPD patients","volume":"9","author":"Minakata","year":"2020","journal-title":"J Clin Med"},{"key":"2026012204421862300_bib80","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/ptj\/86.8.1137","article-title":"Using activity monitors to measure physical activity in free-living conditions","volume":"86","author":"Berlin","year":"2006","journal-title":"Phys Ther"},{"key":"2026012204421862300_bib81","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00008483-200311000-00007","article-title":"A new unsupported upper limb exercise test for patients with chronic obstructive pulmonary disease","volume":"23","author":"Takahashi","year":"2003","journal-title":"J Cardiopulm Rehabil"},{"key":"2026012204421862300_bib82","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/HCR.0b013e31818c3c65","article-title":"Measurement of functional activity in chronic obstructive pulmonary disease: the grocery shelving task","volume":"28","author":"Hill","year":"2008","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026012204421862300_bib83","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00008483-200605000-00013","article-title":"Development of an unsupported arm exercise test in patients with chronic obstructive pulmonary disease","volume":"26","author":"Zhan","year":"2006","journal-title":"J Cardiopulm Rehabil"},{"key":"2026012204421862300_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HCR.0b013e3181ebf302","article-title":"Measurement of peripheral muscle strength in individuals with chronic obstructive pulmonary disease: a systematic review","volume":"31","author":"Robles","year":"2011","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026012204421862300_bib85","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1513\/AnnalsATS.201610-821OC","article-title":"Handgrip strength in chronic obstructive pulmonary disease: associations with acute exacerbations and body composition","volume":"14","author":"Martinez","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026012204421862300_bib86","first-page":"252","article-title":"A conceptual framework for use of increased endurance time during constant work rate cycle ergometry as a patient-focused meaningful outcome in COPD clinical trials","volume":"9","author":"Casaburi","year":"2022","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib87","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/COPD.S77368","article-title":"A review of the most common patient-reported outcomes in COPD\u2014revisiting current knowledge and estimating future challenges","volume":"10","author":"Cazzola","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib88","first-page":"109","article-title":"The COPD Biomarkers Qualification Consortium St George\u2019s Respiratory Questionnaire manuscripts: output of a consortium to advance drug development","volume":"4","author":"Tabberer","year":"2017","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib89","author":"U.S. Food and Drug Administration (FDA)","year":"2018"},{"key":"2026012204421862300_bib90","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201907-1369PP","article-title":"Clinical development and research applications of the Chronic Obstructive Pulmonary Disease Assessment Test","volume":"201","author":"M\u00fcllerov\u00e1","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib91","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/COPD.S235845","article-title":"Patient-reported outcomes (PROs) in COPD: trends and gaps","volume":"15","author":"Afroz","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib92","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/thoraxjnl-2013-204428","article-title":"Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary","volume":"69","author":"Leidy","year":"2014","journal-title":"Thorax"},{"key":"2026012204421862300_bib93","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/15412555.2013.795423","article-title":"Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS","volume":"10","author":"Leidy","year":"2013","journal-title":"COPD"},{"key":"2026012204421862300_bib94","author":"U.S. Food and Drug Administration (FDA)","year":"2020"},{"key":"2026012204421862300_bib95","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"2026012204421862300_bib96","first-page":"576","article-title":"Interpreting Evaluating Respiratory Symptoms in COPD diary scores in clinical trials: terminology, methods, and recommendations","volume":"9","author":"Leidy","year":"2022","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib97","first-page":"551","article-title":"Use of the Evaluating Respiratory Symptoms in COPD as an outcome measure in clinical trials: a rapid systematic review","volume":"8","author":"Bushnell","year":"2021","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026012204421862300_bib98","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/SPC.0000000000000436","article-title":"Multidimensional measurement of breathlessness: recent advances","volume":"13","author":"Williams","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"key":"2026012204421862300_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/thx.2009.118521","article-title":"Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12","volume":"65","author":"Yorke","year":"2010","journal-title":"Thorax"},{"key":"2026012204421862300_bib100","doi-asserted-by":"crossref","first-page":"e025132","DOI":"10.1136\/bmjopen-2018-025132","article-title":"How different are COPD-specific patient reported outcomes, health status, dyspnoea and respiratory symptoms? An observational study in a working population","volume":"9","author":"Nishimura","year":"2019","journal-title":"BMJ Open"},{"key":"2026012204421862300_bib101","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1183\/09031936.00038914","article-title":"Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research","volume":"45","author":"Banzett","year":"2015","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib102","doi-asserted-by":"crossref","first-page":"1600773","DOI":"10.1183\/13993003.00773-2016","article-title":"Comparison of the Dyspnoea-12 and Multidimensional Dyspnoea Profile in people with COPD","volume":"49","author":"Williams","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib103","doi-asserted-by":"crossref","first-page":"1701432","DOI":"10.1183\/13993003.01432-2017","article-title":"Dissecting COPD exacerbations: time to rethink our definition","volume":"50","author":"Celli","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib104","doi-asserted-by":"crossref","first-page":"00136-2019","DOI":"10.1183\/23120541.00136-2019","article-title":"A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations","volume":"5","author":"Mathioudakis","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib106","doi-asserted-by":"crossref","first-page":"1700075","DOI":"10.1183\/13993003.00075-2017","article-title":"Multi-level differential network analysis of COPD exacerbations","volume":"50","author":"Noell","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib107","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40291-019-00413-1","article-title":"Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers","volume":"23","author":"Cazzola","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"2026012204421862300_bib108","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1378\/chest.13-0518","article-title":"Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?","volume":"144","author":"Miravitlles","year":"2013","journal-title":"Chest"},{"key":"2026012204421862300_bib109","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/thoraxjnl-2019-214484","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits","volume":"75","author":"Mathioudakis","year":"2020","journal-title":"Thorax"},{"key":"2026012204421862300_bib110","doi-asserted-by":"crossref","first-page":"00072-2019","DOI":"10.1183\/23120541.00072-2019","article-title":"Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials","volume":"5","author":"Mathioudakis","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib111","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.011","article-title":"Spanish COPD guidelines (GesEPOC) 2021 update. Diagnosis and treatment of COPD exacerbation syndrome","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026012204421862300_bib113","doi-asserted-by":"crossref","first-page":"2102006","DOI":"10.1183\/13993003.02006-2021","article-title":"ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations","volume":"59","author":"Mathioudakis","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib114","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jclinepi.2022.06.016","article-title":"Review finds core outcome set uptake in new studies and systematic reviews needs improvement","volume":"150","author":"Williamson","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026012204421862300_bib115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11739-020-02612-9","article-title":"Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease","volume":"16","author":"Waeijen-Smit","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026012204421862300_bib116","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1164\/rccm.201810-1860SO","article-title":"Chronic obstructive pulmonary disease biomarkers and their interpretation","volume":"199","author":"Stockley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib117","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1164\/rccm.201509-1722PP","article-title":"Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease","volume":"193","author":"Miller","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chest.2016.09.012","article-title":"Biomarker development in COPD: moving from P values to products to impact patient care","volume":"151","author":"Hollander","year":"2017","journal-title":"Chest"},{"key":"2026012204421862300_bib119","author":"European Medicines Agency","year":"2018"},{"key":"2026012204421862300_bib120","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cpt.1540","article-title":"Review of drug development guidance to treat chronic obstructive pulmonary disease: US and EU perspectives","volume":"106","author":"van Haarst","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026012204421862300_bib121","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agust\u00ed","year":"2012","journal-title":"PLoS One"},{"key":"2026012204421862300_bib122","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/B978-0-08-102723-3.00257-2","volume-title":"Encyclopedia of respiratory medicine","author":"Ramakrishnan","year":"2022","edition":"2nd ed."},{"key":"2026012204421862300_bib123","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14789450.2018.1539670","article-title":"Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD)","volume":"15","author":"Moon","year":"2018","journal-title":"Expert Rev Proteomics"},{"key":"2026012204421862300_bib124","doi-asserted-by":"crossref","first-page":"752581","DOI":"10.3389\/fdsfr.2021.752581","article-title":"Moving to a personalized approach in respiratory medicine. From academic research to regulatory intervention","volume":"1","author":"Cazzola","year":"2021","journal-title":"Front Drug Saf Regul"},{"key":"2026012204421862300_bib125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1164\/rccm.201501-0137PP","article-title":"Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung","volume":"192","author":"Yonchuk","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib126","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1165\/rcmb.2018-0245PS","article-title":"Omics and the search for blood biomarkers in chronic obstructive pulmonary disease: insights from COPDGene","volume":"61","author":"Regan","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204421862300_bib127","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.pupt.2010.05.001","article-title":"Biomarkers in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012204421862300_bib128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MCP.0000000000000549","article-title":"Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise","volume":"25","author":"Mannino","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2026012204421862300_bib129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.euprot.2014.04.008","article-title":"Biomarker discovery in asthma and COPD: application of proteomics techniques in human and mice","volume":"4","author":"Haenen","year":"2014","journal-title":"EuPA Open Proteom"},{"key":"2026012204421862300_bib130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/resp.12585","article-title":"Biomarkers, the control panel and personalized COPD medicine","volume":"21","author":"Agusti","year":"2016","journal-title":"Respirology"},{"key":"2026012204421862300_bib131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1513\/AnnalsATS.201705-377FR","article-title":"Recent advances in computed tomography imaging in chronic obstructive pulmonary disease","volume":"15","author":"Bodduluri","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026012204421862300_bib132","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/nm.2971","article-title":"Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression","volume":"18","author":"Galb\u00e1n","year":"2012","journal-title":"Nat Med"},{"key":"2026012204421862300_bib133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chest.2019.06.015","article-title":"Subtyping COPD by using visual and quantitative CT imaging features","volume":"157","author":"Park","year":"2020","journal-title":"Chest"},{"key":"2026012204421862300_bib134","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2589-7500(21)00146-1","article-title":"X-ray dark-field chest imaging for detection and quantification of emphysema in patients with chronic obstructive pulmonary disease: a diagnostic accuracy study","volume":"3","author":"Willer","year":"2021","journal-title":"Lancet Digit Health"},{"key":"2026012204421862300_bib135","doi-asserted-by":"crossref","first-page":"20210207","DOI":"10.1259\/bjr.20210207","article-title":"Lung MRI with hyperpolarised gases: current & future clinical perspectives","volume":"95","author":"Stewart","year":"2022","journal-title":"Br J Radiol"},{"key":"2026012204421862300_bib136","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1465-9921-11-136","article-title":"Therapeutic efficacy of \u03b1-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry","volume":"11","author":"Stockley","year":"2010","journal-title":"Respir Res"},{"key":"2026012204421862300_bib137","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.202205-0927ED","article-title":"Use of computed tomography lung densitometry as an outcome measure for emphysema progression: the case of losartan","volume":"206","author":"Miravitlles","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib138","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(13)70006-7","article-title":"The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study","volume":"1","author":"Coxson","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib139","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S2213-2600(13)70011-0","article-title":"Longitudinal quantitative low-dose CT in COPD: ready for use?","volume":"1","author":"Kauczor","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026012204421862300_bib140","doi-asserted-by":"crossref","first-page":"20406223211014028","DOI":"10.1177\/20406223211014028","article-title":"Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction","volume":"14","author":"Celi","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2026012204421862300_bib141","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12890-015-0138-4","article-title":"Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis","volume":"15","author":"Scott","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2026012204421862300_bib142","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.chest.2021.12.657","article-title":"\u201cCan do, do do\u201d quadrants and 6-year all-cause mortality in patients with COPD","volume":"161","author":"Vaes","year":"2022","journal-title":"Chest"},{"key":"2026012204421862300_bib143","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1164\/rccm.202012-4386LE","article-title":"Triple-therapy trials for chronic obstructive pulmonary disease: methodological considerations in the mortality effect","volume":"203","author":"L\u00f3pez-Campos","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib144","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/13696998.2020.1797755","article-title":"Composite outcome measurement in clinical research: the triumph of illusion over reality?","volume":"23","author":"McKenna","year":"2020","journal-title":"J Med Econ"},{"key":"2026012204421862300_bib145","volume-title":"Handbook on constructing composite indicators: methodology and user guide","author":"Organization for Economic Cooperation and Development (OECD)","year":"2008"},{"key":"2026012204421862300_bib146","volume-title":"Quantitative aspects of psychological assessment: an introduction","author":"Ley","year":"1972"},{"key":"2026012204421862300_bib147","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.conctc.2019.100486","article-title":"Choosing primary endpoints for clinical trials of health care interventions","volume":"16","author":"McLeod","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"2026012204421862300_bib148","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12931-020-01387-z","article-title":"Measuring disease activity in COPD: is clinically important deterioration the answer?","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"2026012204421862300_bib149","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012204421862300_bib150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/pgmj.2006.052399","article-title":"The SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease","volume":"83","author":"Azarisman","year":"2007","journal-title":"Postgrad Med J"},{"key":"2026012204421862300_bib151","doi-asserted-by":"crossref","first-page":"e002152","DOI":"10.1136\/bmjopen-2012-002152","article-title":"Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts","volume":"2","author":"Puhan","year":"2012","journal-title":"BMJ Open"},{"key":"2026012204421862300_bib152","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/hcl110","article-title":"A simple score for assessing stable chronic obstructive pulmonary disease","volume":"99","author":"Esteban","year":"2006","journal-title":"QJM"},{"key":"2026012204421862300_bib153","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.200902-0271OC","article-title":"Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index","volume":"180","author":"Jones","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib154","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1183\/09031936.00189010","article-title":"Development of a decision tree to assess the severity and prognosis of stable COPD","volume":"38","author":"Esteban","year":"2011","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1183\/09031936.00096913","article-title":"Longitudinal assessment in COPD patients: multidimensional variability and outcomes","volume":"43","author":"Casanova","year":"2014","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib156","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2147\/COPD.S247966","article-title":"Early clinically important improvement (ECII) and exacerbation outcomes in COPD patients","volume":"15","author":"Kostikas","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib157","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.1016\/j.rmed.2020.106175","article-title":"COPDCompEx: a novel composite endpoint for COPD exacerbations to enable faster clinical development","volume":"173","author":"Vogelmeier","year":"2020","journal-title":"Respir Med"},{"key":"2026012204421862300_bib158","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/COPD.S101612","article-title":"Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol","volume":"11","author":"Singh","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib159","doi-asserted-by":"crossref","first-page":"00047-2018","DOI":"10.1183\/23120541.00047-2018","article-title":"Preventing clinically important deterioration with single-inhaler triple therapy in COPD","volume":"4","author":"Naya","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026012204421862300_bib160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","article-title":"Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial","volume":"20","author":"Maltais","year":"2019","journal-title":"Respir Res"},{"key":"2026012204421862300_bib161","doi-asserted-by":"crossref","first-page":"107054","DOI":"10.1016\/j.rmed.2022.107054","article-title":"Clinically important deterioration: a composite tool for managing patients with COPD","volume":"205","author":"Cazzola","year":"2022","journal-title":"Respir Med"},{"key":"2026012204421862300_bib162","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/COPD.S295835","article-title":"Treatment of COPD with long-acting bronchodilators: association between early and longer-term clinically important improvement","volume":"16","author":"Vogelmeier","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib163","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.2147\/COPD.S178149","article-title":"Validation of clinical control in COPD as a new tool for optimizing treatment","volume":"13","author":"Soler-Catalu\u00f1a","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib164","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.chest.2019.11.004","article-title":"Evaluation of changes in control status in COPD: an opportunity for early intervention","volume":"157","author":"Soler-Catalu\u00f1a","year":"2020","journal-title":"Chest"},{"key":"2026012204421862300_bib165","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/resp.13811","article-title":"Predictive value of control of COPD for risk of exacerbations: an international, prospective study","volume":"25","author":"Miravitlles","year":"2020","journal-title":"Respirology"},{"key":"2026012204421862300_bib166","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-021-01633-y","article-title":"COPD clinical control: predictors and long-term follow-up of the CHAIN cohort","volume":"22","author":"Calle Rubio","year":"2021","journal-title":"Respir Res"},{"key":"2026012204421862300_bib167","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib168","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-12-40","article-title":"Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review","volume":"12","author":"Westwood","year":"2011","journal-title":"Respir Res"},{"key":"2026012204421862300_bib169","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1164\/rccm.202012-4322LE","article-title":"FEV1 minimum important difference versus minimal detectable difference? In search of the unicorn","volume":"203","author":"Crim","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204421862300_bib170","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib171","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1183\/09031936.00140507","article-title":"Interpretation of treatment changes in 6-minute walk distance in patients with COPD","volume":"32","author":"Puhan","year":"2008","journal-title":"Eur Respir J"},{"key":"2026012204421862300_bib172","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2147\/COPD.S117378","article-title":"Interpreting patient-reported outcomes from clinical trials in COPD: a discussion","volume":"11","author":"Jones","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib173","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fphar.2019.01519","article-title":"Healthcare professionals\u2019 preferred efficacy endpoints and minimal clinically important differences in the assessment of new medicines for chronic obstructive pulmonary disease","volume":"10","author":"Dankers","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026012204421862300_bib174","author":"Mol-Alma","year":"2020"},{"key":"2026012204421862300_bib175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17476348.2018.1398086","article-title":"An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?","volume":"12","author":"Cazzola","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"2026012204421862300_bib176","doi-asserted-by":"crossref","first-page":"e0160770","DOI":"10.1371\/journal.pone.0160770","article-title":"Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort","volume":"11","author":"Cosio","year":"2016","journal-title":"PLoS One"},{"key":"2026012204421862300_bib177","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.arbres.2020.12.010","article-title":"Deconstructing phenotypes in COPD: an analysis of the TRACE cohort","volume":"58","author":"Carrasco Hern\u00e1ndez","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026012204421862300_bib178","doi-asserted-by":"crossref","first-page":"044001","DOI":"10.1088\/1752-7163\/ac15ea","article-title":"Multi-omics study on biomarker and pathway discovery of chronic obstructive pulmonary disease","volume":"15","author":"Tang","year":"2021","journal-title":"J Breath Res"},{"key":"2026012204421862300_bib179","author":"U.S. Food and Drug Administration (FDA)","year":"2018"},{"key":"2026012204421862300_bib180","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/COPD.S330817","article-title":"Treatable traits in COPD\u2014a proposed approach","volume":"16","author":"Cardoso","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204421862300_bib181","doi-asserted-by":"crossref","first-page":"210118","DOI":"10.1183\/20734735.0118-2021","article-title":"The use of treatable traits to address COPD complexity and heterogeneity and to inform the care","volume":"17","author":"Duszyk","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"2026012204421862300_bib182","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12931-022-01954-6","article-title":"COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time","volume":"23","author":"Marques","year":"2022","journal-title":"Respir Res"},{"key":"2026012204421862300_bib183","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/resp.14325","article-title":"Treatable traits in the NOVELTY study","volume":"27","author":"Agust\u00ed","year":"2022","journal-title":"Respirology"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/4\/374\/66436877\/ajrccm_208_4_374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/4\/374\/66436877\/ajrccm_208_4_374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:42:39Z","timestamp":1769074959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/208\/4\/374\/8427894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":183,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,15]]},"published-print":{"date-parts":[[2023,8,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202303-0400so","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2023-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}